Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 14 Aug 2024
Reviewer's report:
This work investigates miR-181a's role in liver cancer, focusing on its regulation of the
extracellular matrix proteoglycan decorin (DCN) and its impact on cell cycle progression. The
research found that DCN is significantly downregulated in liver tissues from patients with
cirrhosis and hepatocellular carcinoma (HCC) compared to healthy controls. Bioinformatics
analysis and luciferase reporter assays confirmed that miR-181a binds to the 3’UTR of
DCN. Overexpression of miR-181a in HuH-7 cells reduced DCN levels, increased cellular
viability, proliferation, and clonogenicity, and promoted cell cycle progression by modulating
key signaling pathways. These results suggest that targeting miR-181a could be a promising
therapeutic strategy for liver cancer. I recommend accepting this manuscript if the authors
address the mentioned issues.
Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 14 Aug 2024
Reviewer's report:
This work investigates miR-181a's role in liver cancer, focusing on its regulation of the
extracellular matrix proteoglycan decorin (DCN) and its impact on cell cycle progression. The
research found that DCN is significantly downregulated in liver tissues from patients with
cirrhosis and hepatocellular carcinoma (HCC) compared to healthy controls. Bioinformatics
analysis and luciferase reporter assays confirmed that miR-181a binds to the 3’UTR of
DCN. Overexpression of miR-181a in HuH-7 cells reduced DCN levels, increased cellular
viability, proliferation, and clonogenicity, and promoted cell cycle progression by modulating
key signaling pathways. These results suggest that targeting miR-181a could be a promising
therapeutic strategy for liver cancer. I recommend accepting this manuscript if the authors
address the mentioned issues.
Please review this paper.
user
Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 14 Aug 2024
Reviewer's report:
This work investigates miR-181a's role in liver cancer, focusing on its regulation of the
extracellular matrix proteoglycan decorin (DCN) and its impact on cell cycle progression. The
research found that DCN is significantly downregulated in liver tissues from patients with
cirrhosis and hepatocellular carcinoma (HCC) compared to healthy controls. Bioinformatics
analysis and luciferase reporter assays confirmed that miR-181a binds to the 3’UTR of
DCN. Overexpression of miR-181a in HuH-7 cells reduced DCN levels, increased cellular
viability, proliferation, and clonogenicity, and promoted cell cycle progression by modulating
key signaling pathways. These results suggest that targeting miR-181a could be a promising
therapeutic strategy for liver cancer. I recommend accepting this manuscript if the authors
address the mentioned issues.
assistant